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Abstract: 
 
Disruption of Cyclin Dependent Kinase 12 (CDK12) is known to lead to defects in 
DNA repair and sensitivity to platinum salts and poly(ADP-ribose) polymerase 1/2 
inhibitors. However, CDK12 has also been proposed as an oncogene in breast 
cancer. We therefore aimed to assess the frequency and distribution of CDK12 
protein expression by immunohistochemistry (IHC) in independent cohorts of breast 
cancer and correlate this with outcome and genomic status. We found that 21% of 
primary unselected breast cancers were CDK12 high, and 10.5% were absent, by 
IHC. CDK12 positivity correlated with HER2 positivity but was not an independent 
predictor of breast cancer specific survival taking HER2 status into account, however 
absent CDK12 protein expression significantly correlated with a triple negative 
phenotype. Interestingly, CDK12 protein absence was associated with reduced 
expression of a number of DDR proteins including ATR, Ku70/Ku80, PARP1, DNA-
PK and gamma-H2AX, suggesting a novel mechanism of CDK12 associated DDR 
dysregulation in breast cancer. Our data suggest that diagnostic IHC quantification of 
CDK12 in BC is feasible, with CDK12 absence possibly signifying defective DDR 
function. This may have important therapeutic implications, particularly for triple 
negative breast cancers. 
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Introduction 
 
Breast cancer (BC) is a complex disease comprising a variety of molecular and 
clinically distinct subtypes. Substantial progress has been made in the management 
of BC mortality over the last 25 years, in part due to improved treatment modalities 
such as endocrine therapies, HER2-targeted therapy and combination 
chemotherapies (1-4). However, a proportion of sporadic primary BC remain difficult 
to treat. Hence, there is an urgent need for stratification and biomarker discovery 
within this cohort. 
 
The CycK/CDK12 (Cyclin K/Cyclin dependent kinase 12) complex is involved in the 
regulation of RNA polymerase II (RNA pol II) and mRNA processing (5-7) and is 
known to protect normal cells from genomic instability by regulating the transcription 
of DNA damage response (DDR) genes (8). Moreover, CDK12 has been postulated 
as a tumor suppressor gene in high-grade serous ovarian cancer (HGSOC), where it 
is one of the only significantly recurrently mutated genes (9). Recurrent point 
mutations have been shown to abrogate the functional activity of CDK12, resulting in 
defects in multiple DNA repair pathways, leading to genomic instability, down-
regulation of some homologous recombination (HR) genes such as BRCA1, FANCI 
or FANCD2 (10,11) and selective sensitivity to both platinum agents and poly (ADP-
ribose) polymerase (PARP1/2) inhibitors (12,13). Indeed, recent data in HGSOC 
suggests that CDK12 inactivated tumors have a unique signature of genomic 
instability characterized by frequent mega-sized gains scattered over the genome, 
that is a result of numerous tandem duplications, indicative of gross defects in DNA 
repair (14).  In addition, recent profiling studies have also identified CDK12 mutations 
in primary and castration resistant prostate cancer that are mutually exclusive with 
other mutations in DNA repair genes (15,16), and akin to HGSOC, result in large 
tandem duplications (14). On the other hand, in BC, CDK12 gene amplification often 
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co-occurs with ERBB2 amplification as both are co-located at locus Ch17q12 
(17,18), and CDK12 overexpression has been correlated with indicators of 
aggressive disease, suggesting that CDK12 could act as a oncogenic driver and 
prognostic biomarker in BC as a result of this co-location (19).  
 
We have previously shown that in BC, CDK12 is recurrently targeted by both DNA 
rearrangements (13% of HER2-amplified BC) and recurrent point mutations (2.6% of 
unselected BC) (13) in a similar manner to HGSOC, and that loss of CDK12 in BC 
models confers sensitivity to PARP1/2 inhibitors in vitro through defects in HR 
(12,13). Loss of CDK12 in BC may therefore signify response to platinum salts 
and/or PARP1/2 inhibitors (12,13).   
 
Here we sought to i) investigate the distribution and frequency of CDK12 protein 
expression in a large series of unselected and Herceptin treated HER2-positive BC, 
using immunohistochemistry (IHC) and examine any correlation with survival; ii) 
evaluate CDK12 protein and mRNA expression with genomic alterations and iii) 
assess whether CDK12 would constitute an oncogenic driver in CDK12 amplified 
tumors. 
 
Materials and Methods 
 
Tissue Microarray Patient Cohorts 
 
Unselected BC 
Primary operable BC cases (n= 1,650) from the Nottingham Tenovus Primary Breast 
Carcinoma Series were utilized as previously described (20-22). Patients were under 
the age of 71 years (median, 55 years), diagnosed between 1986 and 1999, and 
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treated uniformly in a single institution.  Clinicopathological parameters for this series 
are summarized in Supplementary Table S1. 
 
HER2-positive adjuvant trastuzumab series 
The HER2-positive adjuvant trastuzumab series comprises 143 primary operable BC 
from patients presenting between 2003 and 2010 who received adjuvant 
trastuzumab (21). HER2 status was determined according to the American Society of 
Clinical Oncology (ASCO) guidelines as previously described (21).  
Clinicopathological parameters for this series are summarized in Supplementary 
Table S2. 
 
METABRIC Nottingham Breast Cancers 
This series comprised 282 primary BC from Nottingham, which form part of the 
METABRIC cohort (23), (Supplementary Table S3). 
 
Tissue Microarray (TMA) Construction 
Tumor samples were arrayed as previously described (22). Briefly, one core per 
tumor of 0.6 mm thickness was obtained from the most representative areas then re-
embedded in microarray blocks.  
 
CDK12 Immunohistochemistry 
IHC was optimized in-house, using a standard Labelled Polymer technique, on 4µm 
sections of formalin-fixed paraffin embedded (FFPE) normal human tonsil; cell blocks 
containing the MCF7 breast cancer cell line known to express CDK12 transfected 
with a previously validated siRNA pool targeting CDK12 or non-targeting control and 
BT474 cells as a positive control (13) (Fig. 1). Cells were cultured as previously 
described (13) and authenticated by short tandem repeat (STR) typing using the 
StemElite Kit (Promega, UK). Briefly, slides were dewaxed in xylene and rehydrated 
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through graded alcohols. Following heat-induced antigen retrieval in citrate buffer 
(pH 6.0), sections were incubated with a mouse anti-human CDK12 monoclonal 
antibody (1:5000 final dilution, Abcam clone 57311 that was raised against an 
immunogen peptide corresponding to amino acids 1281-1380 of Human CDK12) for 
one hour at room temperature. The staining was visualized using the Dako Flex 
Envision K8002 Kit (Dako), counterstained with Gills hematoxylin (Leica). Sections 
were then dehydrated and mounted.  
 
TMAs were assessed for nuclear CDK12 protein expression in the malignant 
epithelium only, using a modified Allred score (14). Only technically sound cores 
containing >20% invasive tumor cells were included in the analysis. Cores were 
evaluated for both intensity (0 = no stain; 1 = mild; 2 = moderate; 3 = strong), and 
percentage of epithelial cells that stained positive (0 = absent; 1 = background; 2 = 
1–25%; 3 = 26–50%; 4 = 51-75%; 5 = > 75%), Fig. 1. Scores were derived from a 
sum of the intensity and percentage of immunoreactive cells; an average score of 0 
for each tumor was considered negative/absent, and a score of 7 or 8, high, and a 
score of 2-6 as intermediate expression. Scores of 1 were excluded from further 
analysis as these equated to background non-specific staining. IHC staining and 
dichotomization of the other biomarkers included in this study were as per previous 
publications (24-30). Scoring was performed blinded to the study endpoint. 
 
Mining of public datasets 
In order to corroborate our findings, we re-analysed publicly available data from The 
Cancer Genome Atlas (31,32) and METABRIC (23) datasets, to ascertain the 
frequency of CDK12 copy number breakpoints, somatic mutations and methylation 
and correlate these with RNA expression levels. Low and high CDK12 gene 
expression were defined by using an optimal threshold for dichotomizing gene 
expression data as described (33). This was carried out by a stepwise analysis from 
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40 to 60 percentiles at an interval of 5. The cut-offs that displayed the highest 
prognostic significance with log-rank test were selected. In addition, analysis of 
published whole genome shRNA (34) and kinome wide siRNA (35) genetic 
perturbation screens was performed to correlate cell viability of breast cancer cell 
lines with and without CDK12 amplification after CDK12 knockdown. 
 
Assessment of Tandem Duplicator Phenotype 
Affymetrix SNP6.0 copy number data of 224 METABRIC samples were 
preprocessed using PennCNV-affy package 
(affy: http://penncnv.openbioinformatics.org/en/latest/misc/credit/ and segmented 
absolute copy number and ploidy was established with ASCAT 2.1 (36). The two 
tandem duplication phenotypes were established as previously described in Watkins 
et al., 2016 (37).  
 
Statistical Analysis 
Retrospective statistical analysis was performed using SPSS 21.0 statistical software 
(SPSS Inc., Chicago, IL, USA), in compliance with reporting recommendations for 
tumor marker prognostic studies (REMARK) criteria (38). A chi-squared or Fisher’s 
exact test of <0.05 was considered significant. Survival curves were analyzed by the 
method of Kaplan-Meier, with a p-value <0.05 being considered significant with a 10-
year BC specific survival as the endpoint. Multivariate survival analysis was carried 
out using CDK12 expression status, node status, estrogen and progesterone 
receptor (ER/PR) status, HER2 status, age, tumor size and grade. A Student's t-test 
was employed to compare CDK12 expression of mined samples with genetic 
aberrations and normal controls. For comparisons, scores of 0 (absent) and high (7-
8) were compared, given known correlations with high expression and amplification 
(19) and uncertainty regarding intermediate levels of expression. A p-value <0.05 
(two-sided) was considered statistically significant. Differential gene expression 
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analysis of CDK12 absent versus high tumors with gene expression known to be 
involved in DNA repair was performed using data from METABRIC using Limma with 
FDR (False Discovery Rate) multiple correction adjustment. 
 
Results 
 
Distribution of CDK12 expression and clinicopathological correlation 
In the first instance, we assessed CDK12 protein expression by IHC in 696 
unselected BC samples that met the inclusion criteria (described in methods; Fig. 1). 
Overall 73/696 tumors were absent/negative for CDK12 (10.5%) by IHC, and 146 
had CDK12 high expression (21%; Fig. 1A, Supplementary Table S1). Breaking this 
down by subtype, in ER+ patients, 50/510 (9.8%) and 101/510 (19.8%) were CDK12 
absent and high; in HER2+ patients 3/102 (2.9%) and 55/102 (53.9%) were CDK12 
absent and high; and in TN patients, 21/123 (17%) and 17/123 (13.8%) were CDK12 
absent and high respectively. Expression of CDK12 significantly correlated with 
HER2 expression; 96% of CDK12 absent tumors were HER2 negative and 95% of 
HER2 positive tumors had high CDK12 expression (p < 0.001, Chi-Square test). 
Interestingly, no significant correlation of CDK12 expression with ER or PR status 
was observed, but a greater proportion of CDK12 absent tumors showed a triple-
negative phenotype (21/73, 29%) than CDK12 high tumors (17/143, 11.9%, p = 
0.002, Chi-Square test, Supplementary Table S1). There was no association with 
CDK12 high expression and breast cancer specific survival in this cohort (p = 0.354, 
HR = 1.295, 95% CI= 0.75-2.24, Log Rank (Mantel-Cox), Fig. 2A, Supplementary 
Table S4).  
 
These findings were validated in a subset of tumors from the METABRIC cohort of 
unselected BC, in which CDK12 was highly expressed in 63/250 tumors (25.2%) and 
absent in 89/250 tumors (35.6%), Fig. 1 Supplementary Table S3. Again, a 
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significant correlation with HER2 status was observed, with 83/89 (93.3%) of CDK12 
absent tumors being HER2 negative and 13/36 (36.1%) of HER2 amplified tumors 
being CDK12 high (p < 0.0001, Chi-Square test). CDK12 expression also conferred a 
significantly poorer BC specific survival (p < 0.001, HR = 3.161, 95% CI = 1.632-
6.125, Log Rank (Mantel-Cox)) in this cohort in univariate analysis (Fig. 2B). This 
was also significant in multivariate comparisons when taking account for HER2 
positivity (p= 0.038, HR = 2.26, 95% CI = 1.045-4.887, Supplementary Table S4). 
These associations were further corroborated at the mRNA level in a larger cohort of 
primary tumors (n=1961) from METABRIC, where high CDK12 expression was 
associated with a worse BC specific survival (p < 0.001, HR = 1.28, 95% CI = 1.17 - 
1.41, Log Rank (Mantel-Cox), Fig. 2C), however this was not substantiated in 
multivariate analysis when taking HER2 into account (Supplementary Table S4). 
 
We previously identified a proportion of HER2 amplified tumors harbour out-of-frame 
CDK12 fusion genes. As CDK12 is known to map to the smallest region within the 
HER2 amplicon (17,18) these fusions are the result of an amplification breakpoint in 
the HER2 amplicon that converges on CDK12, disrupting its expression (13). We 
also found that tumor cells with loss of CDK12 due to the presence of a breakpoint in 
the HER2 amplicon were sensitive to PARP1/2 inhibitors suggesting that a fraction of 
HER2 amplified patients with CDK12 fusions might also benefit from treatment with 
PARP1/2 inhibitors or platinum chemotherapy (13). To ascertain the frequency of 
CDK12 protein absence in HER2 amplified patients, and possible associations with 
outcome subsequent to anti-HER2 therapy, we assessed CDK12 protein expression 
in HER2 positive patients whom had been treated with Herceptin (21). Overall, 4/119 
(3.4%) tumors were CDK12 absent and 71/119 (59.7%) tumors were CDK12 high 
(Fig. 1A). Lack of CDK12 expression did not improve survival in this cohort following 
Herceptin treatment (p= 0.586; HR= 22.636, 95% CI = 0-1718290, Log Rank 
(Mantel-Cox)), Fig. 2D). 
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In summary (Supplementary Table S1), overall, absence of CDK12 protein 
expression was seen in 10.5% of unselected BC; with a similar proportion of ER+ 
tumours showing absent CDK12 (9.8%). Interestingly, a higher frequency of absent 
CDK12 was seen in TNBC within this unselected cohort (17%); however, no 
association with BC specific survival was seen (p= 0.577, HR= 2, 95% CI = 1.8-3.4, 
Log Rank (Mantel-Cox)). As expected, in all three cohorts analysed, a lower 
proportion of HER2-positive tumours were CDK12 absent. Rather, most HER2 
positive tumours were CDK12 high (protein and mRNA). Although high CDK12 
expression was associated with a worse BC specific survival in these cohorts, this 
association was significant in the METABRIC dataset in multivariate analysis taking 
HER2 status into account, but not borne out in additional datasets.  
 
Association of CDK12 expression and amplification 
We subsequently investigated the associations of CDK12 mRNA expression with 
genomic status in primary BC from METABRIC (23) where there is copy number and 
gene expression data on the same tumor specimen. Of 1979 tumors with matched 
copy number and gene expression data available for CDK12, 208 (10.5%) harboured 
amplification encompassing the CDK12 gene and a concurrent increase in its 
transcript expression, (p< 0.0001; Mann-Whitney U test; Fig. 3A). Of these, 99% 
(205/208) were also HER2 amplified. There was a significant association with BC 
specific survival comparing CDK12 amplified versus non-amplified tumors (p< 
0.0001, Log Rank (Mantel-Cox), (HR = 0.45; 95% CI = 0.35 – 0.57), however, 
similarly to CDK12 protein expression this was lost in multivariate analysis taking 
HER2 status into account (Supplementary Table S4). Assessment of CDK12 protein 
expression by IHC in the METABRIC TMA, stratifying tumors as absent (0) versus 
highly expressed (7-8), however, revealed a significant association between CDK12 
amplification and increased CDK12 protein expression with 12/16 (75%) amplified 
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and 42/120 (35%) non-amplified tumors showing high protein expression, p= 0.0049, 
Fishers exact-test, Fig. 3B).  
 
Recent evidence has pointed to the role of CDK12 as a potential oncogene, given 
that that its amplification is associated with increased protein expression and 
aggressive clinical characteristics (19) and that CDK12 amplified tumors show 
significantly increased CDK12 protein activation (39). To seek any evidence of 
oncogenic addiction to the downstream consequences of activated CDK12, we 
mined publicly available genetic perturbation screens in BC cell line models using 
validated reagents (12,13), to ascertain if CDK12 amplified cells were addicted to 
CDK12 expression and downstream signalling for their survival. Analysis of both 
genome-wide pooled shRNA screen data (34) and siRNA kinome screen data (35) 
failed to identify any association between CDK12 amplification and sensitivity to 
shRNA or siRNA designed to target CDK12 (Fig. 3C-D).  
 
Genetic mechanisms of absent CDK12 expression 
Given our previous findings that disruption of CDK12 can occur as a result of an 
amplification breakpoint in the ERBB2 amplicon that converges on CDK12, disrupting 
its expression (13), we sought to confirm our findings in primary tumors from 
METABRIC (23). Of all cases that showed CDK12 amplification, 14.4% (30/208) 
harboured a breakpoint in CDK12 that was associated with a significant reduction in 
CDK12 transcript levels (p< 0.0001, Mann Whitney U test; Fig. 4A). In HER2 
amplified patients, there was no significant difference in BC specific survival between 
patients with a breakpoint in CDK12 and those without (p= 0.32, Log Rank (Mantel-
Cox) HR= 0.9897, 95% CI= 0.5107-1.918).  
 
To ascertain the frequency of absent CDK12 protein in tumors with copy number 
alterations in CDK12, we intersected the IHC data from a subset of the METABRIC 
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cohort performed above with the available copy number data for CDK12. Of all 
CDK12 amplified tumors, 14% (4/28) showed absent CDK12 protein expression and 
33% (2/6) of tumors with a breakpoint in CDK12 were CDK12 absent. This highlights 
that only a proportion of tumors with CDK12 genomic breakpoints lead to loss of 
CDK12 protein expression.  
 
In HGSOC, CDK12 inactivating mutations have been reported to inactivate gene 
expression and consequently abrogate HR DNA repair pathways (10,11,14). 
Examination of DNA sequencing data from The Cancer Genome Atlas (TCGA) (32) 
identified CDK12 mutations in 1.5% (20/1373) of unselected BC (Fig. 4B), 
(Supplementary Table S5 and S6).  These included 12 missense mutations, and 8 
truncating mutations. Overall, 45% (9/20 (8 truncating and 1 missense) were 
predicted to disrupt protein function, and of these 25% (2/9) were seen in patients 
with triple-negative disease, whereas the remaining patients had ER+ or ER-/HER2+ 
disease. In contrast with recent data in HGSOC (11), predicted deleterious mutations 
did not correlate with reduced transcript expression, or with down-regulation of DNA 
damage response (DDR) genes, (Supplementary Table S7). CDK12 promoter 
methylation was a rare event seen in 1/696 (0.14%) of unselected BC 
(Supplementary Table S6). We next looked for other genomic alterations that would 
lead to absent CDK12 protein expression by interrogation of METABRIC cases with 
copy number and miRNA expression (23,40). This identified that heterozygous loss 
of CDK12 accounted for 7.1% (6/84) cases with absent CDK12 protein expression, 
however this was not enriched in the CDK12 absent group compared to the CDK12 
high group (p>0.999, Fishers exact test). In addition, of the 14/162 miRNA’s, that are 
known or predicted targets of CDK12, present in METABRIC (40) none showed 
correlation with CDK12 protein expression after multiple correction (Supplementary 
Table S8), suggesting there are additional mechanisms that lead to CDK12 protein 
loss. 
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Absent CDK12 protein expression is associated with reduced protein 
expression of genes involved in DNA repair  
Although predicted deleterious mutations in CDK12 did not correlate with reduced 
expression of DDR genes (see above), we assessed whether loss of CDK12 protein 
expression correlated with a reduction in the transcript expression of DNA repair 
proteins or biomarkers of DNA damage in the unselected series of BC cases (Table 
1). Although no significant correlations were observed (after multiple testing 
correction) with DDR genes at the mRNA level (Supplementary Table S9), absent 
CDK12 protein was significantly correlated with reduced protein expression of ATR, 
APE1, nuclear and cytoplasmic SMC6, Ku70/Ku80, DNA-PK and H2AX nuclear 
positivity. Absent CDK12 protein expression also significantly correlated with both 
cleaved PARP1 (p= 0.003, Chi-Square) and non-cleaved PARP1 (p= 0.005, Chi-
Square) expression suggesting that PARP1 levels are higher in tumors with absent 
CDK12. Interestingly, absent CDK12 expression also correlated with a decreased 
expression of TP53 (p= 0.001; Chi-Square) and RB1 (p= 0.003, Chi-Square), 
however there was no significant correlation between absent CDK12 protein and 
TP53 mutations in the METABRIC cohort of tumors (17.5% CDK12 absent and 
26.4% CDK12 high tumours harbouring TP53 mutations p= 0.2779, Fishers exact 
test).   
 
Since absent CDK12 protein expression was seen in 17% of TNBC within our 
analysis, we assessed this subset of tumors for correlations with the expression of 
DNA repair proteins as above. Even within this relative small subset, some significant 
correlations were still seen with DDR genes at the protein level: ATR (p= 0.018, Chi-
Square); Ku70/Ku80 (p= 0.01, Chi-Square); and loss or decrease in nuclear and 
cytoplasmic SMC6 (p= 0.045, Chi-Square; Table 1). Of note comparison of CDK12 
absent (0) and intermediate (2-6) levels of expression together as one group versus 
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high (7-8) failed to identify any significant associations with DNA repair genes both in 
unselected BC and TNBC (Supplementary Table S10). This suggests that functional 
loss of CDK12 is only observed in tumors with absent CDK12 protein expression in 
breast cancer and not low levels of CDK12 expression. 
 
It has been shown that in HGSOC CDK12 mutations are consistently associated with 
a particular genomic instability pattern characterized by hundreds of tandem 
duplications of up to 10 megabases (Mb) in size, dubbed the ‘CDK12 TD-plus 
phenotype’ (14). Assessment of this pattern in both unselected and TNBC with 
absent CDK12 protein failed to identify any association with large numbers and sizes 
of tandem duplications (Fig. 4C-D). Together these results suggest that absent 
CDK12 protein in BC is associated with some defects in DNA repair related genes, 
however the resultant genomic scars are likely to be different to that seen in HGSOC 
(11).  
 
Discussion 
 
In this study, we were able to analyze, for the first time, the distribution of CDK12 
protein in cohorts of primary BC. We show that high CDK12 expression is 
significantly correlated with HER2 status and that absent CDK12 is associated with a 
triple-negative phenotype and disruption of proteins involved in DNA repair. 
 
The significant correlation of CDK12 with HER2 expression in these data is not 
surprising, since CDK12 is known to map to the smallest region within the HER2 
amplicon (17,18). Therefore, although we observed significant correlations with 
CDK12 expression and patient survival, this significance was subsequently lost when 
HER2 positivity was taken into account. However, this association was substantiated 
in the METABRIC cohort at the protein level, suggesting investigation of additional 
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cohorts are warranted.  It has been postulated that CDK12 may act in an oncogenic 
manner, given observed associations with amplification and increased transcript and 
protein expression and subsequent phosphorylation (19,39). This may perhaps occur 
through its reported roles in transcription through phosphorylation of RNA Pol II and 
regulation of pre-mRNA processing (5,7). By analyzing published siRNA and shRNA 
cell viability screens, using validated reagents (12,13) we show here that amplified 
cells are not addicted to CDK12 for their survival. We concede the assay length 
(average 4-7 days) in these experiments, may be too short to detect a loss of viability 
to depletion of a cyclin dependent kinase and additional time may be required to 
reduce DNA repair protein expression and accumulate damage required to affect 
viability. Interestingly, a recent study has suggested that CDK12 does act in an 
oncogenic manner in HER2 amplified cells by promoting cell invasion via alternative 
splicing and subsequent down-regulation of the long isoform of DNAJB6 (41), 
suggestive of a mechanism by which CDK12 acts in an oncogenic manner to 
promote cell invasiveness. Of note, elevated levels of CDK12 in HER2 positive 
tumors have been a proposed reason why tumors arising in BRCA1 carriers are 
usually ERBB2-negative, given elevated expression would oppose the defects in HR 
mediated by BRCA1 loss (34). 
 
We have shown previously that a proportion of HER2-positive tumors harbor 
inactivating (out-of-frame) fusion genes in CDK12 that are due to a copy number 
breakpoint in the HER2 amplicon converging on CDK12, resulting in a significant 
decrease in both transcript and protein levels (13). Furthermore, cell lines with 
breakpoints in CDK12 that result in loss of protein expression are sensitive to 
PARP1/2 inhibitor therapy, due to impaired HR mediated DNA repair (13). By 
assessing the distribution of CDK12 protein expression in CDK12 amplified breast 
cancers in the METABRIC cohort, we identified 14% that were CDK12 absent. 
Moreover, of the tumors with a breakpoint in CDK12, 33% had absent CDK12 protein 
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expression. Whilst the numbers we were able to assess are small, this nevertheless 
suggests a proportion of HER2 positive patients show absent CDK12 protein as a 
result of both copy number breakpoints and additional mechanisms. Overall, our data 
suggest there may be a small proportion of HER2-positive patients that may benefit 
from treatment with DNA damage response targeted therapies such as PARP1/2 
inhibitor therapy. 
 
Recent data in HGSOC has shown that CDK12 point mutations inactivate gene 
expression subsequently abrogating HR DNA repair pathways (10,11).  Although in 
our study CDK12 mutations did not themselves correlate with decreased expression 
of DNA repair genes (perhaps due to residual CDK12 activity, given some of these 
are not associated with loss of heterozygosity), we show that BC with absent CDK12 
protein show down-regulation of a number of genes involved in functional HR DNA 
repair at the protein level, suggesting that absent CDK12 protein in BC may also be 
associated with HR defects. Although we were unable to assess all proteins known 
to be dysregulated in CDK12 mutant HGSOC such as RAD51, FANCI and FANCD2, 
it is reasonable to postulate that CDK12 may have other targets, including DNA 
repair proteins themselves, phosphorylation of which is required for protein stability. 
Lack of any observed associations at the mRNA level, may be due to small numbers 
in the study, however, our observed associations warrant further investigation in 
larger cohorts. Recent evidence in HGSOC points to a unique signature of genomic 
instability in CDK12 mutated tumors that is indicative of gross defects in DNA repair 
characterized by tens to hundreds of large tandem duplications scattered throughout 
the genome, although this was not observed in CDK12 mutated breast cancers (14). 
Consistent with this, we observed no correlation with large tandem duplications of 
neither all BC nor TNBC specifically. It is intriguing however that we observed absent 
CDK12 protein in 17% of TNBC from the unselected primary BC analyzed in this 
study. Of course, this could be a consequence of the small number of cases 
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included, however CDK12 inactivation may play a role in a subset of TNBC’s 
possibly through mechanisms distinct from those observed in HGSOC.  
 
In conclusion, we have shown that a subset of HER2-positive patients show absent 
CDK12 protein expression and have shown an enrichment of absent CDK12 protein 
expression in TNBC. Moreover, we have provided evidence that absent CDK12 
expression is associated with defects in DNA repair proteins. These results suggest 
that CDK12 IHC could potentially be useful, once validated in sufficiently powered 
studies, for stratification of patients for treatment with DDR targeted therapies. 
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Figure Legends 
 
Figure 1: Distribution of CDK12 protein expression in breast cancer 
A, Modified CONSORT diagram depicting the distribution of CDK12 positive and 
negative breast cancers in each of the cohorts analysed. B, Representative 
micrographs of CDK12 protein expression in i, MCF7 cell line treated with non-
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targeting siRNA controls; ii, MCF7 cell line treated with previously validated siRNA 
against CDK12 (13); iii. BT474 CDK12 amplified cells all at x400 magnification; iv, 
tonsil positive control (x 200 magnification). v-viii, Representative images of staining 
intensity in primary breast cancers, where CDK12 expression was quantified using a 
modified Allred score, which assessed both intensity (highest score = 3) and 
percentage positivity (highest score = 5): (v) negative; (vi) 1+; (vii) 2+; and (viii) 3+; 
all images at 200x magnification. A score of 0 was considered absent and a score of 
7 or 8, as high expression. 
 
Figure 2: CDK12 positive breast cancer has a poorer survival in univariate 
analysis 
Kaplan-Meier curves showing breast cancer specific survival for CDK12 high (7-8) 
versus negative (0) breast cancers asses by IHC in A, Nottingham unselected 
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primary breast cancer series (n= 203); B, tumors from METABRIC (n= 140); C, Gene 
expression correlations of CDK12 low versus high from METABRIC (n= 1961) and D, 
HER2-positive tumors treated with Herceptin (n= 75).  
 
Figure 3: CDK12 amplified cells are not dependent on CDK12 expression for 
their survival 
A, Scatter dot plot depicting a significant association of CDK12 transcript expression 
with gene amplification (n= 208) versus no amplification (n= 1769) (error bars 
represent median with the interquartile range). B, bar-chart depicting a significant 
increase of CDK12 protein expression as measured by IHC in CDK12 amplified 
tumors (n= 16) compared to non-amplified (n= 103). C-D, Relative cell viability after 
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CDK12 silencing in CDK12 amplified (Campbell, n= 8; Marcotte n= 14) versus non-
amplified cell lines (Campbell, n= 19; Marcotte n= 40), showing no significant 
difference in cell survival from c) Marcotte et al (34) and d) Campbell at al (35). 
 
 
Figure 4: CDK12 protein loss is associated with DNA repair defects in breast 
cancer 
A, Box and whisker plot (min-max) showing a significant decrease in CDK12 
transcript levels in HER2-amplified tumors with breakpoints (n= 30) in CDK12 
compared with no breakpoints (n= 178) from METABRIC. B, Lollipop diagram 
depicting the distribution of CDK12 mutations in breast cancer (red= frameshift and 
nonsense mutations, green= non-synonymous coding mutations). C, Scatter dot plot 
diagrams showing significant associations between CDK12 absent (n= 74) (IHC 
score 0) versus CDK12 high (n= 51) (IHC score 7-8) in unselected METABRIC 
tumors with large tandem duplication score, indicative of gross genomic defects. D, 
Scatter dot plot diagrams showing significant associations between CDK12 absent 
(n= 8) (IHC score 0) versus CDK12 high (n= 4) (IHC score 7-8) in TNBC from 
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METABRIC, with large tandem duplication score, indicative of gross genomic 
defects. 
 
Table 1: Association of CDK12 expression with DNA repair proteins in 
unselected and TNBC 
 CDK12 Absent 
(0) 
No. of cases 
(%) 
CDK12 High 
(7/8) 
No. of cases 
(%) 
p-value 
Unselected Series 
BRCA1 (n= 170) 
0.249      Negative 27 (51.9) 50 (42.4) 
     Positive 25 (48.1) 68 (57.6) 
PARP1 cleaved (n= 170) 
0.003**      Negative 18 (30) 13 (11.8) 
     Positive 42 (70) 97 (88.2) 
PARP1 non-cleaved (n= 175)   
0.005**      Negative 36 (62.1) 46 (39.3) 
     Positive 22 (37.9) 71 (60.7) 
ATR (n= 173)   
<0.001**      Negative 46 (70.8) 45 (41.7) 
     Positive 19 (29.2) 63 (58.3) 
APE1 (n= 89)   
0.02*      Negative 10 (38.5) 10 (15.9) 
     Positive 16 (61.5) 53 (84.1) 
Ku70/Ku80 (n= 153)   
0.001**      Negative 18 (34.0) 11 (11.0) 
     Positive 35 (66.0) 89 (89.0) 
DNA-PK (n= 156)   
0.002**      Negative 17 (32.1) 12 (11.7) 
     Positive 36 (67.9) 91 (88.3) 
SMC6 cytoplasmic (n= 166)   
0.002**      Negative 30 (54.5) 33 (29.7) 
     Positive 25 (45.5) 78 (70.3) 
SMC6 nuclear (n= 166)   
< 0.001**      Negative 33 (60.0) 34 (30.6) 
     Positive 22 (40.0) 77 (69.4) 
γH2AX (n= 150)   
0.002**      Negative 24 (47.1) 22 (22.2) 
     Positive 27 (52.9) 77 (77.8) 
TP53 (n= 209)   
0.001**      Negative 56 (80.0) 80 (57.6) 
     Positive 14 (20.0) 59 (42.4) 
CHEK1 cytoplasmic (n= 103)   
0.321      Negative 29 (50.9) 44 (42.7) 
     Positive 28 (49.1) 59 (57.3) 
CHEK1 nuclear (n= 161)   
0.927      Negative 48 (84.2) 87 (83.7) 
     Positive 9 (15.8) 17 (16.3) 
CHEK2 (n= 108)   
0.345      Negative 31 (50.8) 63 (58.3) 
     Positive 30 (49.2) 45 (41.7) 
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Triple Negative Breast Cancer 
BRCA1 (n= 28) 0.430 
     Negative 10 (71.4) 8 (57.1) 
     Positive 4 (28.6) 6 (42.9) 
PARP1 cleaved (n= 28) 0.378 
     Negative 8 (50.0) 4 (33.3) 
     Positive 8 (50.0) 8 (66.7) 
PARP1 non-cleaved (n= 29) 0.103 
     Negative 11 (68.8) 5 (38.5) 
     Positive 5 (31.2) 8 (61.5) 
ATR (n= 33) 0.018* 
     Negative 18 (90.0) 7 (53.8) 
     Positive 2 (10.0) 6 (46.2) 
APE1 (n= 17) 0.453 
     Negative 2 (25.0) 1 (11.1) 
     Positive 6 (75.0) 8 (88.9) 
Ku70/Ku80 (n= 27) 0.010* 
     Negative 8 (47.1) 0 (0.0) 
     Positive 9 (52.9) 10 (100.0) 
DNA-PK (n= 31) 0.283 
     Negative 6 (37.5) 3 (25.0) 
     Positive 10 (62.5) 12 (75.0) 
SMC6 cytoplasmic (n= 31) 0.018* 
     Negative 9 (60.0) 3 (23.1) 
     Positive 6 (40.0) 13 (76.9) 
SMC6 nuclear (n= 31) 0.045* 
     Negative 11 (73.3) 6 (37.5) 
     Positive 4 (26.7) 10 (62.5) 
γH2AX (n= 29) 0.089 
     Negative 9 (60.0) 4 (28.6) 
     Positive 6 (40.0) 10 (71.4) 
TP53 (n= 36) 0.187 
     Negative 12 (63.2) 7 (41.2) 
     Positive 7 (36.8) 10 (58.8) 
CHEK1 cytoplasmic (n= 27) 0.384 
     Negative 8 (47.1) 3 (30.0) 
     Positive 9 (52.9) 7 (70.0) 
CHEK1 nuclear (n= 28) 0.068 
     Negative 17 (100.0) 9 (81.8) 
     Positive 0 (0.0) 2 (18.2) 
CHEK2 (n= 32) 0.961 
     Negative 13 (68.4) 9 (69.2) 
     Positive 6 (31.6) 4 (30.8) 
 
 
Supplementary Tables: 
Supplementary Table S1: CDK12 expression in relation to clinicopathological 
parameters for the unselected TMA series 
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Supplementary Table S2: CDK12 expression in relation to clinicopathological 
parameters for the HER2-positive Herceptin treated series 
 
Supplementary Table S3: CDK12 expression in relation to clinicopathological 
parameters for the METABRIC TMA series 
 
Supplementary Table S4: Univariate and multivariate analysis of CDK12 in the TMA 
cohorts 
 
Supplementary Table S5: CDK12 mutations in breast cancer. Taken from 
cBioportal (42,43). 
 
Supplementary Table S6: Correlations of CDK12 mutations, methylation, gene 
expression and ERBB2 copy number in primary breast cancers from TCGA 
 
Supplementary Table S7: Correlations of CDK12 mutations and gene expression of 
DNA repair genes in primary tumors from METABRIC. P values from heteroscedastic 
2-tailed, t-test 
 
Supplementary Table S8: Correlations of CDK12 protein expression, and miRNA 
expression in primary tumors from METABRIC. Wilcoxon rank P values are corrected 
for multiple testing. 
 
 
Supplementary Table S9: Correlations of CDK12 protein expression and gene 
expression of DNA repair genes in primary tumors from METABRIC. Limma analysis 
corrected for multiple testing. 
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Supplementary Table S10: Association of CDK12 absent and intermediate (0, 2-6) 
versus high (7-8) expression with DNA repair proteins in unselected and TNBC. P 
values from Fishers exact test. 
 
